-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Kiniksa Pharmaceuticals International, plc quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q2 2017 to Q2 2024.
- Kiniksa Pharmaceuticals International, plc Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $6.21M.
- Kiniksa Pharmaceuticals International, plc Income Tax Expense (Benefit) for the twelve months ending June 30, 2024 was -$7.79M, a 95.9% increase year-over-year.
- Kiniksa Pharmaceuticals International, plc annual Income Tax Expense (Benefit) for 2023 was -$30.7M, a 82.2% increase from 2022.
- Kiniksa Pharmaceuticals International, plc annual Income Tax Expense (Benefit) for 2022 was -$172M, a 12543% decline from 2021.
- Kiniksa Pharmaceuticals International, plc annual Income Tax Expense (Benefit) for 2021 was $1.39M, a 73.1% decline from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)